表紙
市場調查報告書

癌症分析和途徑:技術和全球市場

Cancer Profiling and Pathways: Technologies and Global Markets

出版商 BCC Research 商品編碼 133421
出版日期 內容資訊 英文 255 Pages
訂單完成後即時交付
價格
Back to Top
癌症分析和途徑:技術和全球市場 Cancer Profiling and Pathways: Technologies and Global Markets
出版日期: 2019年03月25日內容資訊: 英文 255 Pages
簡介

全球癌症分析技術市場預計從2018年的452億美元,到2023年以14.9%年複合成長率達906億美元。

本報告提供全球癌症分析和途徑市場相關調查,市場現狀與市場結構,市場規模,技術趨勢等,以及參與企業的簡介等相關資訊。

第1章 簡介

第2章 摘要和亮點

第3章 概要

  • 簡介
  • 生物標記
  • 指南
  • 篩檢試驗
  • 癌症的早期發現和診斷
  • 途徑分析
  • 透過途徑分析來關聯癌症疾病
  • 分子分析
  • 癌症分析
  • 病理學的分類
  • 分子分析方法
  • 未來的目標

第4章 目前分析技術

  • 基因學
  • 基因分析
  • 微陣列
  • 比較基因混合化
  • 一鹼變異多型(SNP)
  • Multi-color FISH
  • DNA定序
  • 高通量定序
  • 其他定序技術
  • 對癌症的適用
  • 新興微陣列技術
  • 未來

第5章 表觀基因體學分析

第6章 蛋白質體學

第7章 醣質學

第8章 代謝體學

第9章 生物資訊學,資料庫,途徑分析

第10章 癌症分析和臨床開發

  • 生物標記
  • 癌症和生物標記

第11章 市場

  • 全球DNA診斷市場
  • 癌症診斷市場
  • 癌症/腫瘤分析市場
  • 癌症生物標記檢驗市場
  • 基因學市場
  • SNP遺傳基因型決策與分析市場
  • 微陣列/生物晶片市場
  • DNA定序市場
  • PCR市場 其他

本網頁內容可能與最新版本有所差異。詳細情況請與我們聯繫。

目錄
Product Code: BIO073C

Report Highlights:

The global market for cancer profiling technologies should grow from $45.2 billion in 2018 to $90.6 billion by 2023 with a compound annual growth rate (CAGR) of 14.9% for the period of 2018-2023.

Genomics market should grow from $19.0 billion in 2018 to $35.5 billion by 2023 with a CAGR of 13.3% for the period of 2018-2023.

Proteomics market should grow from $13.1 billion in 2018 to $22.6 billion by 2023 with a CAGR of 11.6% for the period of 2018-2023.

Report Scope:

Cancer biomarkers have gained significant importance in the drug-development process, and the market is an emerging segment. To gain an understanding of the market dynamics, market size and competitive landscape, a detailed analysis of cancer biomarker market and cancer profiling technologies and new developments is needed. Microarray technologies provide analysis of tens of thousands of molecules for a variety of assays, including drug binding, molecular interactions, enzyme activity and pathway identification. These microarrays, which include DNA microarrays, protein microarrays, tissue microarrays, low complexity microarrays and carbohydrate microarrays, are excellent tools for gene expression profiling, biomarker profiling and diagnostics. 

Pharmaceutical and biotechnology researchers use microarrays to streamline drug target identification, selection, validation and predictive testing. Rapid growth in the clinical research and diagnostic devices markets holds great potential for applications of microarray technology, including basic research, clinical trials and diagnostic devices. This report examines various microarray platforms and the technologies that are utilized to detect DNA and proteins for the purpose of drug discovery, disease diagnosis and disease monitoring. This report also examines companies that are actively developing and marketing microarray instrumentation or microarray biochips.

The report categorizes the biomarkers and profiling market and provides market data, market drivers, trends and opportunities, top-selling products, key players and competitive outlook. This report will also provide market tables and also provides company profiles.

This report analyzes the cancer profiling and pathways market: technologies market, tools market, and application market (diagnosis, drug development and discovery). This report also examines recent studies, microRNA detection and profiling, clinically oriented microRNA profiling in several human cancers. The report covers epigenetic, methylation and miRNA products in development, products in clinical trials, currently marketed and clinical-stage development products. Relationship between miRNAs and epigenetics is also examined. This report categorizes the market for epigenetics, forecasting the market value in revenue by analyzing the current and future trends in research, diagnostics and therapeutics industries. This report also looks at SNPs analysis instruments, reagents, software and services, providing information critical to understanding the business behind this new technology.

The following technologies and segments are excluded from this report: detailed instruments, pharmacogenomics, combinatorial chemistry, biochip, bioinformatics and high-throughput screening (HTS). Uses of emerging technologies in drug discovery such as lab-on-a-chip (LOAC), nanotechnology, and RNA interference (RNAi) also are not discussed here.

Report Includes:

  • 91 tables
  • An overview of the global market for cancer profiling and pathways
  • Analyses of global market trends, with data from 2017 and 2018, and projections of compound annual growth rates (CAGRs) through 2023
  • Discussion of products in this market, newly emerging tools, diagnostics and therapeutics, and their impacts on the market
  • Examination of evolving methods, such as microarray analysis, multiplex PCR, and quantitative real-time PCR, which are integral to deciphering molecular mechanisms involved in gene function, biological development, and disease progression, and are important tools in the discovery and development of new drug targets and diagnostic biomarkers
  • Identification of important cancer profiling techniques, market shares by types of products on the market, and market shares by company, as well as types of cancers and biomarkers
  • Coverage of epigenetic, methylation, and miRNA products in development, products in clinical trials and currently marketed, and clinical-stage development products
  • Company profiles of key players in the market

Table of Contents

Chapter 1: Introduction

  • Study Goals and Objectives
  • Reasons for Doing the Study
  • Scope of Report
  • Intended Audience
  • Methodology
  • Information Sources
  • Analyst's Credentials
  • BCC Custom Research
  • Related BCC Research Reports

Chapter 2: Summary and Highlights

  • Cancer Profiling and Pathways

Chapter 3: Overview

  • Introduction
    • Biomarkers
  • Guidelines
    • Screening Tests
    • Early Detection and Diagnosis of Cancer
  • Pathway Profiling
    • Linking Cancer Disease through Pathway Profiling
  • Molecular Profiling
    • Historical Facts
    • Molecular Profiles
  • Cancer Profiling
    • Challenges
  • Clinical Utility of Molecular Profiling
    • Pathological Classification
    • Molecular Profiling Approaches
  • Cancer Profiling: Future Goals

Chapter 4: Current Profiling Techniques

  • Genomics
    • Genomic Profiling
    • Microarrays
    • Comparative Genomic Hybridization (CGH)
    • Key Companies
    • Key Players
    • Microarrays to Clinical Problems
  • Single Nucleotide Polymorphism (SNP)
    • Multi-color FISH
    • Companies
  • DNA Sequencing
    • Emerging DNA Sequencing Technologies
    • High-throughput Sequencing
    • Other Sequencing Technologies
    • Cancer Applications
    • Next-Gen Sequencing
    • Next-Generation Companies
    • ABI/SOLiD
    • Other Methods
    • Patents and Sequencing
  • Summary
    • Next-Generation Sequencing Technologies
    • Next-Generation Sequencing: Future
  • Genomics and Cancer-Some Examples
    • Mutations Predicting Resistance to Targeted Therapies
    • Sequencing and the Clinic
  • Transcriptomic Profiling
    • Microarray-based Gene Expression Profiling
    • Tiling Arrays
    • qRT-PCR
  • Cancer Applications
  • Emerging Microarray Technologies
  • Future

Chapter 5: Epigenomic Profiling

  • Overview and Introduction to the Epigenetics Landscape
    • Cancer Applications
    • DNA Methylation
    • microRNA
    • Epigenetic Changes and Cancer Stem Cells
    • Epigenetic Therapy for Cancer
    • Leading Epigenetic Companies
    • Epigenetics and MicroRNA Profiling-Finding Pathways to Treatment
    • MicroRNAs and Therapeutic Applications in Cancer
    • MicroRNAs as Prognostic and Therapeutic Biomarkers
    • Anti-Cancer Drugs and microRNA Targets
    • Case Study: Epigenetic Silencing of the Intronic microRNA Mir-342 in Colorectal Cancer
    • Diagnostic and Therapeutic microRNA Strategies in Cancer
    • Therapeutic Potential
    • Therapeutic Strategies
    • MicroRNAs in Disease Diagnostics
    • Circulating microRNAs
    • MicroRNA Profiling Methods
    • Clinical microRNA Diagnostics
    • MicroRNAs in Therapeutics
    • MicroRNA Patents and Outlook
    • Future
  • Methylation Markers
    • DNA Methylation, an Epigenetic Process
    • Current Methods and Products
    • Clinical Implications
    • Future Directions
    • Epigenetic Diagnostic Development
    • Epigenetic Drugs
    • HDAC Inhibitors
    • Epigenetic Therapeutic Development
    • Key Players

Chapter 6: Proteomics

  • Proteomics and Protein Profiling
    • Proteomics Protein Profiling Approaches
    • Techniques
    • Applications of Proteomic Techniques in Cancer Research
    • Technologies and Limitations
    • Proteomics and Initiatives
    • Cancer Applications
    • Proteomics in the Treatment of Cancer
    • Clinical Applications of Proteomics
    • Proteomic Approaches in Therapeutic Targets
    • Key Players
    • Proteomics-Based Diagnostic Products
    • Proteomic Research Centers
    • Clinical Trial Using Proteomics Technologies for Personalized Medicine
    • Proteomics and Medicine
    • Proteomics Market

Chapter 7: Glycomics

  • What is Glycomics?
  • Techniques
    • Analytical High-Throughput Technologies
    • Emergence of Glycoarrays
    • Glycoinformatics
  • Biomedical Applications
  • Glycomics's Relationship with Other "Omics" Technologies
  • Glycomics for Biomarker Discovery
  • Cancer and Glycomics
    • Glycomics-Biomarkers for Ovarian Cancer
  • U.S. Patents on Glycomics

Chapter 8: Metabolomics

  • What is Metabolomics?
  • Metabolome
    • Techniques
    • Detection Methods
    • Metabolomics and Drug Discovery
    • Biomarker Identification

Chapter 9: Bioinformatics, Databases and Pathway Analysis

Chapter 10: Cancer Profiling and Clinical Development

  • Biomarkers
    • Cancer and Biomarkers

Chapter 11: Market

  • Global DNA Diagnostics Market
  • The Cancer Diagnostics Market
    • Cancer Diagnostic Tests
  • The Cancer/Tumor Profiling Market
    • Personalized Medicine
  • Cancer Biomarker Testing Market
    • Genomics Market
  • SNP Genotyping and Analysis Market
    • Microarray/Biochips Market
    • Diagnostic Microarrays
    • DNA Sequencing Market
    • PCR Market
    • Epigenetics and Market
  • miRNA Market
    • Epigenetics and Cancer Market and Future Growth
    • Proteomics in the Pharma Industry
    • Protein Microarrays and Trends
    • The Metabolomics Market
    • Future
    • Conclusion

List of Tables

  • Summary Table: Global Cancer Profiling Technologies Market, by Type, Through 2023
    • Table 1: Technical Approaches for Tumor Molecular Profiling
    • Table 2: Different Tools for Molecular Profiling of Cancer
    • Table 3: Genomics: Technologies
    • Table 4: Applications Market
    • Table 5: Segment Types
    • Table 6: List of Techniques/Tools for Genomic Profiling
    • Table 7: Global Genomics Market for Cancer Profiling Technologies, Through 2023
    • Table 8: Commonly Used DNA Microarrays
    • Table 9: Genomic Tests
    • Table 10: Selected Companies with Microarray Technologies
    • Table 11: Key Companies
    • Table 12: Companies with Sequencing Technologies Next-Generation Sequencers
    • Table 13: Sequencing Patents Awarded
    • Table 14: Mutations Identified in Cancer
    • Table 15: Consortium Listed Responsibilities
    • Table 16: Transcriptomic Techniques
    • Table 17: miRNA and siRNA-a Comparison
    • Table 18: Epigenetic Drugs Approved by the U.S. FDA
    • Table 19: HDAC Inhibitors
    • Table 20: Selected Epigenetic Companies
    • Table 21: Currently Used microRNA Techniques
    • Table 22: MicroRNA Expression in Cancer
    • Table 23: Epi-miRNAs Regulating Effectors of the Epigenetic Machinery
    • Table 24: List of Predicted Targets That are Known Genes Affected in Colon Cancer
    • Table 25: List of Predicted Targets That are Known Genes Affected in Pancreatic Cancer
    • Table 26: miRNAs Differentially Expressed Between CRC and Normal Colorectal Tissue
    • Table 27: miRNAs Differentially Expressed Between Normal Colon and Early-Stage Colorectal Cancer (Stages I and II)
    • Table 28: miRNAs Differentially Expressed in Early- (I and II) Vs Late-Stage (III and IV) Disease
    • Table 29: Pathways Targeted by CRC miRNAs
    • Table 30: MicroRNAs as Prognostic Indicators and Therapeutic Targets: Potential Effect on Breast Cancer Management
    • Table 31: MicroRNAs (miRs) with Altered Expression in Ovarian Carcinoma
    • Table 32: MicroRNA-based Therapeutics: Development Status
    • Table 33: Selected microRNAs in Development and Cancer
    • Table 34: microRNA Patents
    • Table 35: Global microRNA Market for Cancer Profiling Technologies, Through 2023
    • Table 36: Selected Companies for miRNA-Specific Tools and Reagents
    • Table 37: Intrinsic Classification of Breast Cancer, by Gene Expression Profiles and Cell Surface Hormonal Expression
    • Table 38: Select Epigenetic-based Diagnostic Companies
    • Table 39: Selected Methylation Tests for Cancer
    • Table 40: Global Epigenetics Market for Cancer Profiling Technologies, Through 2023
    • Table 41: Epigenetic Drugs for Cancer-Approved/Late-Stage Clinical Trials
    • Table 42: Methylation Markers in Development
    • Table 43: Selected Companies with Methylation Products
    • Table 44: Methylation Markers/Tests-Patents
    • Table 45: Biomarker Identified Using Two-Dimensional Electrophoresis (2-DE)
    • Table 46: Biomarker Identified using Mass Spectroscopy (MS)
    • Table 47: Antibody Array Vendors
    • Table 48: Global Proteomics Market for Cancer Profiling Technologies, Through 2023
    • Table 49: The Seven Tumor Glycome Laboratories
    • Table 50: Clinical Trials and Glycomics
    • Table 51: U.S. Patents on Glycomics
    • Table 52: Key Predictive Biomarkers for Trastuzumab Therapy
    • Table 53: Predictive Biomarkers for EGFR TKI Therapies in Lung Cancer
    • Table 54: Global DNA Diagnostics Market, Through 2023
    • Table 55: Cancer Profiling Market: Segment Types
    • Table 56: Global Cancer Profiling Technologies Market, Through 2023
    • Table 57: Cancer Profiling Market: Applications
    • Table 58: Cancer Profiling Market: Technologies
    • Table 59: Global Biomarkers Market, Through 2023
    • Table 60: Selected Players
    • Table 61: U.S. Biomarker Cancer Testing Market, Through 2023
    • Table 62: Global Genomics Market for Cancer Profiling Technologies, Through 2023
    • Table 63: Global SNP Genotyping Market, Through 2023
    • Table 64: Global Biochips Market, Through 2023
    • Table 65: Microarray Markets
    • Table 66: Some Major BioChip Companies
    • Table 67: Microarrays: Modalities
    • Table 68: Global Diagnostic Microarray Market for Cancer Profiling Technologies, Through 2023
    • Table 69: Some Commercially Available Cancer Diagnostic Devices Based on Microarray Technology
    • Table 70: Microarray Technologies: Key Companies and Products
    • Table 71: Global DNA Microarray Market, Through 2023
    • Table 72: MicroArray Products
    • Table 73: Global Next-Generation Sequencing Market, Through 2023
    • Table 74: The Next-Generation Sequencing (NGS) Market: Platforms
    • Table 75: Next-Generation Sequencing-Based Target Enrichment Industry Company Platform Method
    • Table 76: Noninvasive Prenatal Diagnostics Potential Future Competitors
    • Table 77: Global Polymerase Chain Reaction Market, Through 2023
    • Table 78: Key PCR Companies
    • Table 79: Real-Time (QRTPCR) PCR Selected Companies
    • Table 80: Global Digital (d)PCR and qPCR Market, Through 2023
    • Table 81: Global Epigenetics Market, Through 2023
    • Table 82: Epigenetics Arrays and Selected Cancer Profiling Companies
    • Table 83: Epigenetic Drugs: Approved by the FDA and Commercially Available
    • Table 84: Epigenetics and Selected Companies
    • Table 85: Epigenetic Diagnostic Tests
    • Table 86: Global miRNA Market for Cancer Profiling Technologies, Through 2023
    • Table 87: miRNA Market Segments
    • Table 88: Selected Companies with Methylation Products
    • Table 89: Global Proteomics Market for Cancer Profiling Technologies, Through 2023
    • Table 90: Selected Companies Offering, Developing or Partnering to Develop Companion Diagnostics

List of Figures

  • Summary Figure: Global Cancer Profiling Technologies Market, by Type, 2017-2023
    • Figure 1: Global Genomics Market for Cancer Profiling Technologies, 2017-2023
    • Figure 2: Global microRNA Market for Cancer Profiling Technologies, 2017-2023
    • Figure 3: Global Epigenetics Market for Cancer Profiling Technologies, 2017-2023
    • Figure 4: Global Proteomics Market for Cancer Profiling Technologies, 2017-2023
    • Figure 5: Global DNA Diagnostics Market, 2017-2023
    • Figure 6: Global Biomarkers Market, 2017-2023
    • Figure 7: U.S. Biomarker Cancer Testing Market, 2017-2023
    • Figure 8: Global Genomics Market for Cancer Profiling Technologies, 2017-2023
    • Figure 9: Global SNP Genotyping Market, 2017-2023
    • Figure 10: Global Biochips Market, 2017-2023
    • Figure 11: Global Diagnostic Microarray Market for Cancer Profiling Technologies, 2017-2023
    • Figure 12: Global DNA Microarray Market, 2017-2023
    • Figure 13: Global Next-Generation Sequencing Market, 2017-2023
    • Figure 14: Global Polymerase Chain Reaction Market, 2017-2023
    • Figure 15: Global Digital (d)PCR and qPCR Market, 2017-2023
    • Figure 16: Global Epigenetics Market, 2017-2023
    • Figure 17: Global miRNA Market for Cancer Profiling Technologies, 2017-2023
    • Figure 18: Global Proteomics Market for Cancer Profiling Technologies, 2017-2023
Back to Top